Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided in vivo delivery of interferon gamma for cancer immunotherapy.

[1]  M. Hentze,et al.  Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. , 2010, Blood.

[2]  Ji-Hee Kim,et al.  Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. , 2010, Biomaterials.

[3]  Chandana Mohanty,et al.  Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. , 2010, Biomaterials.

[4]  Christoph Alexiou,et al.  Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles - a pilot study. , 2010, Anticancer research.

[5]  C. Serna,et al.  Liver and brain imaging through dimercaptosuccinic acid-coated iron oxide nanoparticles. , 2010, Nanomedicine.

[6]  Miqin Zhang,et al.  Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. , 2010, Advanced drug delivery reviews.

[7]  Wei Yang,et al.  Responsiveness of Stromal Fibroblasts to IFN-γ Blocks Tumor Growth via Angiostasis1 , 2009, The Journal of Immunology.

[8]  S. Soenen,et al.  Assessing cytotoxicity of (iron oxide-based) nanoparticles: an overview of different methods exemplified with cationic magnetoliposomes. , 2009, Contrast media & molecular imaging.

[9]  T. Xia,et al.  Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.

[10]  P. Couvreur,et al.  Nanocarriers’ entry into the cell: relevance to drug delivery , 2009, Cellular and Molecular Life Sciences.

[11]  P. Morais,et al.  Expression patterns of cell adhesion molecules in mice's lung after administration of meso-2,3-dimercaptosuccinic acid-coated maghemite nanoparticles. , 2009, Journal of nanoscience and nanotechnology.

[12]  C. Serna,et al.  Effect of nanoparticle and aggregate size on the relaxometric properties of MR contrast agents based on high quality magnetite nanoparticles. , 2009, The journal of physical chemistry. B.

[13]  Sabino Veintemillas-Verdaguer,et al.  The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells , 2009, Nanotechnology.

[14]  V. Labhasetwar,et al.  Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. , 2008, Biomaterials.

[15]  V. Shastri,et al.  The effect of silica nanoparticle-modified surfaces on cell morphology, cytoskeletal organization and function. , 2008, Biomaterials.

[16]  D. F. Barber,et al.  Cytokine adsorption/release on uniform magnetic nanoparticles for localized drug delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[18]  P. Morais,et al.  In vitro biological activities of anionic gamma-Fe2O3 nanoparticles on human melanoma cells. , 2008, Journal of nanoscience and nanotechnology.

[19]  D. Leslie-Pelecky,et al.  Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. , 2008, Molecular pharmaceutics.

[20]  F. Lázaro,et al.  The role of dipolar interaction in the quantitative determination of particulate magnetic carriers in biological tissues , 2007, Physics in medicine and biology.

[21]  Christoph Alexiou,et al.  Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting. , 2007, Anticancer research.

[22]  J. Santamaría,et al.  Magnetic nanoparticles for drug delivery , 2007 .

[23]  M. Amiji,et al.  Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. , 2007, Journal of pharmaceutical sciences.

[24]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[25]  F. Lázaro,et al.  Bioinorganic transformations of liver iron deposits observed by tissue magnetic characterisation in a rat model. , 2006, Journal of inorganic biochemistry.

[26]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[27]  L Trahms,et al.  Quantification of magnetic nanoparticles by magnetorelaxometry and comparison to histology after magnetic drug targeting. , 2006, Journal of nanoscience and nanotechnology.

[28]  Christopher J. Destache,et al.  Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System , 2006, Journal of Neuroimmune Pharmacology.

[29]  Abraham Ulman,et al.  Adverse effects of citrate/gold nanoparticles on human dermal fibroblasts. , 2006, Small.

[30]  Christoph Alexiou,et al.  Targeting cancer cells: magnetic nanoparticles as drug carriers , 2006, European Biophysics Journal.

[31]  J. Dobson.  Magnetic nanoparticles for drug delivery , 2006 .

[32]  F. Lázaro,et al.  Magnetic characterisation of rat muscle tissues after subcutaneous iron dextran injection. , 2005, Biochimica et biophysica acta.

[33]  Ajay Kumar Gupta,et al.  Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.

[34]  H. Hofmann,et al.  Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system , 2005 .

[35]  P. Morais,et al.  Morphological analysis of mouse lungs after treatment with magnetite-based magnetic fluid stabilized with DMSA , 2005 .

[36]  M. Smyth,et al.  Cytokines in cancer immunity and immunotherapy , 2004, Immunological reviews.

[37]  H. Ikeda,et al.  The critical role of type‐1 innate and acquired immunity in tumor immunotherapy , 2004, Cancer science.

[38]  J. Riemer,et al.  Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. , 2004, Analytical biochemistry.

[39]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[40]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.

[41]  K. Schroder,et al.  Interferon- : an overview of signals, mechanisms and functions , 2004 .

[42]  Hao Zeng,et al.  Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. , 2004, Journal of the American Chemical Society.

[43]  R. Ramesh,et al.  Cytokine- and chemokine-based gene therapy for cancer. , 2003, Current opinion in molecular therapeutics.

[44]  Jessie L.-S. Au,et al.  Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.

[45]  Christoph Alexiou,et al.  Magnetic Drug Targeting—Biodistribution of the Magnetic Carrier and the Chemotherapeutic agent Mitoxantrone after Locoregional Cancer Treatment , 2003 .

[46]  P. Morais,et al.  Light microscopy and magnetic resonance characterization of a DMSA-coated magnetic fluid in mice , 2002 .

[47]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[48]  C. Alexiou,et al.  Magnetic drug targeting: biodistribution and dependency on magnetic field strength ☆ , 2002 .

[49]  Angus G. Dalgleish,et al.  Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy , 2002, Cancer Immunology, Immunotherapy.

[50]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[51]  D. Castro,et al.  The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck. , 2002, Archives of otolaryngology--head & neck surgery.

[52]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[53]  W. Yokoyama,et al.  In vivo developmental stages in murine natural killer cell maturation , 2002, Nature Immunology.

[54]  Liping Yang,et al.  Analysis of In Situ NK Cell Responses During Viral Infection1 , 2001, The Journal of Immunology.

[55]  C. Alexiou,et al.  Locoregional cancer treatment with magnetic drug targeting. , 2000, Cancer research.

[56]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[57]  L. Yu,et al.  The role of LY49 NK cell subsets in the regulation of murine cytomegalovirus infections. , 1999, Journal of immunology.

[58]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[59]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Huhn,et al.  Preclinical experiences with magnetic drug targeting: tolerance and efficacy. , 1996, Cancer research.

[61]  P Reichardt,et al.  Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. , 1996, Cancer research.

[62]  T. Mosmann,et al.  The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.

[63]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[64]  R. Schreiber,et al.  Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.

[65]  Govind Rao,et al.  Comparison of Trypan Blue Dye Exclusion and Fluorometric Assays for Mammalian Cell Viability Determinations , 1993, Biotechnology progress.

[66]  R. Kurzrock,et al.  Clinical toxicity of interferons in cancer patients: a review. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  E Borenfreund,et al.  Toxicity determined in vitro by morphological alterations and neutral red absorption. , 1985, Toxicology letters.

[68]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[69]  W. Kuebler,et al.  The effect of DMSA-functionalized magnetic nanoparticles on transendothelial migration of monocytes in the murine lung via a beta2 integrin-dependent pathway. , 2010, Biomaterials.

[70]  K. Schroder,et al.  Interferon-gamma: an overview of signals, mechanisms and functions. , 2004, Journal of leukocyte biology.

[71]  Christoph Alexiou,et al.  Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. , 2003, Journal of drug targeting.

[72]  B. Amsden,et al.  Interferon-gamma therapy: evaluation of routes of administration and delivery systems. , 2002, Journal of pharmaceutical sciences.

[73]  H. P. Kang,et al.  Kim, S. et al. In vivo developmental stages in murine natural killer cell maturation. Nat. Immunol. 3, 523-528 , 2002 .

[74]  B. Amsden,et al.  Interferon‐γ therapy: Evaluation of routes of administration and delivery systems , 2002 .

[75]  M. Smyth,et al.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.

[76]  G. Beatty,et al.  Regulation of tumor growth by IFN-gamma in cancer immunotherapy. , 2001, Immunologic research.

[77]  G. Beatty,et al.  Regulation of tumor growth by IFN-γ in cancer immunotherapy , 2001 .

[78]  A. Ohta,et al.  The critical role of Th1-dominant immunity in tumor immunology , 2000, Cancer Chemotherapy and Pharmacology.

[79]  R. Schreiber,et al.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[80]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.